secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K/A
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001490978-23-000095
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q2 revenue falls 8.5% to $35.2M; raises software guidance, cuts drug discovery outlook
--------------------------------------------------------------------------------

- GAAP net income of $4.3M vs loss of $47.7M; non-GAAP net loss widened to $56.8M from $43.8M.
- Total revenue $35.2M, down 8.5% YoY; drug discovery revenue fell 31% to $5.8M.
- 2023 software revenue growth guidance raised to 15-18%; drug discovery revenue guidance cut to $50-70M from $70-90M.
- IND cleared for CDC7 inhibitor SGR-2921; Phase 1 trial in AML/MDS planned for 2023.
- Margaret Dugan appointed CMO; Zai Lab collaboration not advanced, program wholly-owned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097823000095/0001490978-23-000095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097823000095/sdgr-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001490978-23-000095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer